Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (SIZOMUS)

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.

cladribine
alemtuzumab
tecfidera
fingolimod
ocrelizumab
  • 0 views
  • 16 Mar, 2022
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome (OBIT)

The main gold of this study is to lead a multicentric, prospective study, to evaluate the diagnostic quality of tears in children with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) during a longitudinal follow-up.

  • 1 views
  • 25 Mar, 2022
  • 1 location
Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

Considering the accumulated data on the pathogenesis of multiple sclerosis, indicating a significant role of B cells in the progression of the disease, the use of monoclonal antibodies to CD20 antigen, administered intrathecally to achieve adequate B-lymphodepletion in the barrier tissues can increase the duration of the recurrence-free course of …

cyclophosphamide
disease or disorder
rituximab
  • 0 views
  • 22 Oct, 2021
  • 1 location
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.

  • 0 views
  • 02 Dec, 2021
  • 1 location
Bacille Calmette-Gu rin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the "dream" of a world free of MS. As …

clinically isolated syndrome
disease or disorder
myelopathies
  • 0 views
  • 19 Jun, 2021
  • 1 location
RIS International Cohort

an event at ten years. The patients who offer a higher risk of developing a first clinical demyelinating event were identified such as male sex, young age, the presence of oligoclonal bands (BOCs) in

  • 0 views
  • 06 Jun, 2022
  • 1 location
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis

to predict future disease course are extremely useful. The only cerebrospinal fluid (CSF) prognostic biomarker currently used in clinical practice are oligoclonal bands (OCB) that can predict

optic neuritis
oligoclonal bands
optical coherence tomography
MRI
disease or disorder
  • 0 views
  • 19 Oct, 2021
  • 1 location